Nachrichten zur MEDIVIR AB Aktie

Medivir to present at the Pareto Securities Healthcare Conference

Stockholm, Sweden, September 16, 2024 — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for…

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2024

“Our study shows a superior profile with the combination of fostrox and Lenvima in advanced liver cancer” April – June Financial summary…

Number of shares and votes in Medivir AB on 28 June 2024

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed…

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024

In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 7 May…

MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2024

”Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA,…

Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to…